What this pack is
DUPIXENT is the brand name in this record; dupilumab is the generic name. Read both together with the dosage form (injectable product).
PACK CHECK · MARKET FIRST
DUPIXENTGeneric namedupilumab
How this medicine works
The U.S. DUPIXENT label classifies dupilumab as an interleukin-4 receptor alpha antagonist. This term helps read the product’s pharmacologic category; it does not predict an individual’s symptoms, suitability, response speed, co-use choice or whether treatment should change.
Read source: United States ↗Current regulatory record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- DUPIXENT
- Generic name
- dupilumab
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Route documented in the linked source label
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A vial concentration, unit-per-mL value or device marking identifies the exact labelled product. It does not calculate an individual's amount, timing, administration, missed-use action, combination or switch.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · U.S. DailyMed public label (updated 22 Apr 2026)
Dupilumab 300 mg/2 mL (150 mg/mL) per pre-filled syringe; carton of 2 single-dose pre-filled syringes
- Product code
- NDC 0024-5914-01
- Form and route
- subcutaneous injection: single-dose pre-filled syringe with needle shield · subcutaneous (label product-identity field)
- Container
- single-dose pre-filled syringe with needle shield
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-22; actual marketing, stock and availability are not established.
- dupilumab
- 300 mglabelled amount per pre-filled syringe; not an individual injection amount or conversion
- Package
- 2 single-dose pre-filled syringes per carton
- Labelled appearance
- blue-green carton · carton of 2 single-dose pre-filled syringes · imprint DUPIXENT / dupilumab / 300 mg/2 mL / NDC 0024-5914-01
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
DUPIXENT label reading: first distinguish 300 mg/2 mL, 150 mg/mL and the exact delivery device
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module reads only the DUPIXENT 300 mg/2 mL carton of two single-dose pre-filled syringes, NDC and label route in the current U.S. DailyMed public label. It provides no individual injection amount, schedule, missed-use handling, start, stop, co-use, switch or purchase plan.
- For checking, keep DUPIXENT, dupilumab, 300 mg/2 mL (150 mg/mL), NDC 0024-5914-01, two single-dose pre-filled syringes, route and target market together. Seeing only “dupilumab,” “300 mg,” or a similar carton colour does not establish that a pen device, strength, package or product in another country is the same.
- 300 mg/2 mL is the labelled total amount and volume for this exact product, while 150 mg/mL is the concentration; neither is an instruction for how much or how often an individual should use it. Do not calculate, combine or substitute another strength or device from package numbers.
- This label panel is for a single-dose pre-filled syringe with needle shield, not a pre-filled pen. Device operation, preparation, missed use, damage, an unusual appearance, storage or disposal questions require the current instructions for the actual product and clinician/pharmacist guidance; do not use this webpage in place of the product instructions.
- If concerned about an allergy-like reaction, breathing difficulty, swelling of the face or throat, marked illness or another acute problem, use local emergency or medical support immediately; do not independently continue, pause or change an injectable product from general web information.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. DUPIXENT dupilumab public label (Sanofi-aventis U.S.; updated 22 Apr 2026) ↗Current regulatory record · reviewed 2026-08-20
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-20FDA: DUPIXENT dupilumab U.S. prescribing information (2026) ↗Current regulatory record · reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about DUPIXENT (dupilumab). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
DUPIXENT is the brand in this record and dupilumab is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg/mL, mg per vial or a total volume describes the labelled concentration or pack identity of an injectable product. It is not an individual infusion amount, preparation instruction or schedule.
Check the exact injection presentation
For an injectable or infusion presentation, verify the route, concentration, container and device in the exact current label. Do not transfer, share, prepare or substitute it from this page.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a severe reaction, fainting, difficulty breathing or sudden worsening symptoms around an injection or infusion, use the local treatment team or emergency service now. Do not wait for a website reply or alter preparation, infusion or another medicine yourself.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. DUPIXENT dupilumab public label (Sanofi-aventis U.S.; updated 22 Apr 2026) ↗Current regulatory record · reviewed 2026-08-20
- FDA: DUPIXENT dupilumab U.S. prescribing information (2026) ↗Current regulatory record · reviewed 2026-08-20
HOW IT WORKS · NOT A TREATMENT PLAN
Mechanism reading for dupilumab: the label classifies it as an interleukin-4 receptor alpha antagonist
- A pharmacologic class cannot replace professional review of the actual diagnosis, symptom severity, prior reactions, co-medication or exact device in hand. Do not self-add, stop, alternate or replace an injectable product because a mechanism name is the same or different.
- When the same generic name appears in different strengths, packages, devices or markets, mechanism does not prove those products are interchangeable. For a comparison, first have a professional check the exact product, current label for the target market and complete medicine list.
- A mechanism term also cannot explain an injection-site concern, an acute illness or whether treatment should continue. With an acute or marked concern, use local emergency or clinical pathways and have the responsible team assess the actual product.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. DUPIXENT dupilumab public label (Sanofi-aventis U.S.; updated 22 Apr 2026) ↗Current regulatory record · reviewed 2026-08-20
- FDA: DUPIXENT dupilumab U.S. prescribing information (2026) ↗Current regulatory record · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
DUPIXENTdupilumab
This page includes an exact current U.S. public-label package panel for DUPIXENT, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The FDA 2026 DUPIXENT label lists Initial U.S. Approval: 2017. This year only locates the U.S. product-label history; it does not establish approval, supply, sale eligibility, originator/generic relationship or individual suitability in another market.
FDA: DUPIXENT dupilumab U.S. prescribing information (2026) ↗Current DailyMed public label updated
DailyMed lists 22 Apr 2026 as the Updated date for this U.S. public label. This page uses that version only to check 300 mg/2 mL, NDC 0024-5914-01 and the two-syringe carton; it does not establish actual marketing, stock, purchase or an individual use plan.
DailyMed (NLM): current U.S. DUPIXENT dupilumab public label (Sanofi-aventis U.S.; updated 22 Apr 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current public label and one exact pre-filled-syringe carton panel linkedThis page displays only the DUPIXENT dupilumab 300 mg/2 mL (150 mg/mL), NDC 0024-5914-01 carton of two single-dose pre-filled syringes with needle shield. It does not authenticate a product or establish actual marketing, stock, purchase, individual injection amount, schedule, device operation, switching or interchangeability.
Mainland China, EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the U.S. label, BLA, NDC, English brand, device name or package image; every market requires separate checking against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
With the same generic name dupilumab, can a pre-filled syringe, a pre-filled pen or another strength be self-switched by milligram amount?
No. Device, strength, package, label version, market and prescription are all parts of product identity. A shared generic name or similar milligram amount does not create a conversion or substitution relationship; take the actual product and full medicine list to a pharmacist or prescribing team.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.